{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:24:39Z","timestamp":1790954679724,"version":"4.1.0"},"reference-count":49,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Cidara Therapeutics, Inc."},{"name":"Melinta Therapeutics LLC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Time to bloodstream clearance is a critical prognostic indicator in various infections, yet limited data exist on the relationship between time to mycological clearance and outcomes in candidemia. This study aimed to assess the association between the duration of candidemia and outcomes in adult, hospitalized patients receiving empiric echinocandin treatment across US hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, multicenter study using the PINCI AI Healthcare Database (1\/2016\u20134\/2019) was conducted. Inclusion criteria: hospitalized adults (\u226518 years) with Candida spp. identified on a clinical blood culture who received empiric echinocandin therapy (\u00b12 days of index Candida spp. blood culture) for \u22653 days. Outcomes assessed were in-hospital mortality, length of stay, and hospital costs. The associations between increasing duration of candidemia relative to a single day of candidemia and outcomes were examined.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 867 patients met the criteria. Multivariable analysis showed that patients with candidemia lasting more than 1 day had significantly higher mortality, longer length of stay, and higher hospital costs compared to those with only 1 day of candidemia. For each additional day of candidemia, the adjusted odds of in-hospital mortality increased by 3%, the adjusted median hospital length of stay after index collection day increased by 1.0 days, and the adjusted median total costs after index collection day increased by $3006.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Prolonged candidemia is associated with worse patient outcomes and higher healthcare costs. Further large-scale studies are needed to confirm these findings given the exploratory and observational nature of this study.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf472","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:35:26Z","timestamp":1756467326000},"page":"75-85","source":"Crossref","is-referenced-by-count":6,"title":["Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4730-0655","authenticated-orcid":false,"given":"Thomas P","family":"Lodise","sequence":"first","affiliation":[{"name":"Pharmacy Practice, Albany College of Pharmacy and Health Sciences , Albany, New York ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin W","family":"Garey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy , Houston, Texas ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jalal A","family":"Aram","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Melinta Theraputics , Parsippany-Troy Hills, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5079-1814","authenticated-orcid":false,"given":"Brian H","family":"Nathanson","sequence":"additional","affiliation":[{"name":"OptiStatim, LLC , Longmeadow, Massachusetts ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Redell","sequence":"additional","affiliation":[{"name":"Scientific Affairs, Melinta Theraputics , Parsippany-Troy Hills, New Jersey ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"2026020904073094800_ciaf472-B1","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJMoa1801550","article-title":"Changes in prevalence of health care-associated infections in U.S. hospitals","volume":"379","author":"Magill","year":"2018","journal-title":"N Engl J Med"},{"key":"2026020904073094800_ciaf472-B2","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B3","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"2026020904073094800_ciaf472-B4","doi-asserted-by":"crossref","first-page":"11786337211026927","DOI":"10.1177\/11786337211026927","article-title":"Candida bloodstream infections: changes in epidemiology and increase in drug resistance","volume":"14","author":"Kotey","year":"2021","journal-title":"Infect Dis (Auckl)"},{"key":"2026020904073094800_ciaf472-B5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diagmicrobio.2012.10.003","article-title":"Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance(R)) registry, 2004\u20132008","volume":"74","author":"Pfaller","year":"2012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026020904073094800_ciaf472-B6","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ijantimicag.2011.02.016","article-title":"Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in intensive care unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008\u20132009)","volume":"38","author":"Pfaller","year":"2011","journal-title":"Int J Antimicrob Agents"},{"key":"2026020904073094800_ciaf472-B7","doi-asserted-by":"crossref","first-page":"106229","DOI":"10.1016\/j.jinf.2024.106229","article-title":"Attributable mortality of candidemia\u2014results from the ECMM Candida III multinational European Observational Cohort Study","volume":"89","author":"Salmanton-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"key":"2026020904073094800_ciaf472-B8","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/infdis\/jiaa502","article-title":"Invasive candidiasis species distribution and trends, United States, 2009\u20132017","volume":"223","author":"Ricotta","year":"2021","journal-title":"J Infect Dis"},{"key":"2026020904073094800_ciaf472-B9","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/civ933","article-title":"Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America","volume":"62","author":"Pappas","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B10","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1056\/NEJMoa066906","article-title":"Anidulafungin versus fluconazole for invasive candidiasis","volume":"356","author":"Reboli","year":"2007","journal-title":"N Engl J Med"},{"key":"2026020904073094800_ciaf472-B11","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3390\/jof10100685","article-title":"Tracking candidemia trends and antifungal resistance patterns across Europe: an in-depth analysis of surveillance systems and surveillance studies","volume":"10","author":"Odoj","year":"2024","journal-title":"J Fungi (Basel)"},{"key":"2026020904073094800_ciaf472-B12","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1093\/cid\/cis021","article-title":"Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials","volume":"54","author":"Andes","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/1469-0691.12039","article-title":"ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients","volume":"18 Suppl 7","author":"Cornely","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026020904073094800_ciaf472-B14","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12879-015-1143-1","article-title":"Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis","volume":"15","author":"Auzinger","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2026020904073094800_ciaf472-B15","doi-asserted-by":"crossref","first-page":"R253","DOI":"10.1186\/cc10514","article-title":"Anidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasis","volume":"15","author":"Kett","year":"2011","journal-title":"Crit Care"},{"key":"2026020904073094800_ciaf472-B16","doi-asserted-by":"crossref","first-page":"705","DOI":"10.2165\/11584810-000000000-00000","article-title":"Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients","volume":"29","author":"Reboli","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"2026020904073094800_ciaf472-B17","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.jiac.2021.06.017","article-title":"Comparison of mortality between echinocandins and polyenes for an initial treatment of candidemia: a systematic review and meta-analysis","volume":"27","author":"Kato","year":"2021","journal-title":"J Infect Chemother"},{"key":"2026020904073094800_ciaf472-B18","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1086\/502581","article-title":"Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance","volume":"26","author":"Morgan","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026020904073094800_ciaf472-B19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.cmi.2019.04.024","article-title":"Morbidity and mortality of candidaemia in Europe: an epidemiologic meta-analysis","volume":"25","author":"Koehler","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2026020904073094800_ciaf472-B20","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-024-00503-3","article-title":"Invasive candidiasis","volume":"10","author":"Lass-Fl\u00f6rl","year":"2024","journal-title":"Nat Rev Dis Primers"},{"key":"2026020904073094800_ciaf472-B21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1186\/s13054-019-2497-3","article-title":"Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project","volume":"23","author":"Bassetti","year":"2019","journal-title":"Crit Care"},{"key":"2026020904073094800_ciaf472-B22","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11046-022-00624-x","article-title":"Candidemia in internal medicine: facing the new challenge","volume":"187","author":"Brescini","year":"2022","journal-title":"Mycopathologia"},{"key":"2026020904073094800_ciaf472-B23","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s11739-017-1783-9","article-title":"Independent risk factors for mortality in critically ill patients with candidemia on Italian internal medicine wards","volume":"13","author":"Sbrana","year":"2018","journal-title":"Intern Emerg Med"},{"key":"2026020904073094800_ciaf472-B24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejim.2016.08.020","article-title":"Epidemiology and outcome of candidemia in internal medicine wards: a regional study in Italy","volume":"34","author":"Tedeschi","year":"2016","journal-title":"Eur J Intern Med"},{"key":"2026020904073094800_ciaf472-B25","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s15010-015-0845-z","article-title":"Epidemiology, clinical characteristics, and outcome of candidemia in a tertiary referral center in Italy from 2010 to 2014","volume":"44","author":"Barchiesi","year":"2016","journal-title":"Infection"},{"key":"2026020904073094800_ciaf472-B26","doi-asserted-by":"crossref","first-page":"e0125149","DOI":"10.1371\/journal.pone.0125149","article-title":"The effect on mortality of fluconazole or echinocandins treatment in candidemia in internal medicine wards [corrected]","volume":"10","author":"De Rosa","year":"2015","journal-title":"PLoS One"},{"key":"2026020904073094800_ciaf472-B27","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13054-020-2766-1","article-title":"Risk factors for candidemia: a prospective matched case-control study","volume":"24","author":"Poissy","year":"2020","journal-title":"Crit Care"},{"key":"2026020904073094800_ciaf472-B28","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1093\/clind\/15.3.414","article-title":"Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality","volume":"15","author":"Fraser","year":"1992","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B29","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/jof7020079","article-title":"Candida albicans-the virulence factors and clinical manifestations of infection","volume":"7","author":"Talapko","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"2026020904073094800_ciaf472-B30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/504810","article-title":"Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study","volume":"43","author":"Garey","year":"2006","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B31","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archsurg.137.12.1353","article-title":"Epidemiology and prognostic determinants of bloodstream infections in surgical intensive care","volume":"137","author":"Harbarth","year":"2002","journal-title":"Arch Surg"},{"key":"2026020904073094800_ciaf472-B32","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/cid\/cis305","article-title":"Septic shock attributed to Candida infection: importance of empiric therapy and source control","volume":"54","author":"Kollef","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B33","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.clinthera.2014.06.028","article-title":"Effects of empiric antifungal therapy for septic shock on time to appropriate therapy for Candida infection: a pilot study","volume":"36","author":"Micek","year":"2014","journal-title":"Clin Ther"},{"key":"2026020904073094800_ciaf472-B34","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1128\/AAC.49.9.3640-3645.2005","article-title":"Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality","volume":"49","author":"Morrell","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2026020904073094800_ciaf472-B35","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1097\/MJT.0b013e3181a1afb7","article-title":"The effect of time to antifungal therapy on mortality in candidemia associated septic shock","volume":"16","author":"Patel","year":"2009","journal-title":"Am J Ther"},{"key":"2026020904073094800_ciaf472-B36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.riam.2022.12.002","article-title":"Candida bloodstream infection in patients with cancer: a retrospective analysis of an 11-year period","volume":"40","author":"Vazquez-Olvera","year":"2023","journal-title":"Rev Iberoam Micol"},{"key":"2026020904073094800_ciaf472-B37","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cmi.2014.07.006","article-title":"Early initiation of appropriate treatment is associated with increased survival in cancer patients with Candida glabrata fungaemia: a potential benefit from infectious disease consultation","volume":"21","author":"Farmakiotis","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2026020904073094800_ciaf472-B38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12941-023-00561-7","article-title":"Persistent bacteremia predicts poor outcomes among neutropenic patients with carbapenem-resistant gram-negative bloodstream infections receiving appropriate therapy","volume":"22","author":"Sathya Kumar","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2026020904073094800_ciaf472-B39","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/cid\/ciaa439","article-title":"Is early clearance of blood cultures the be-all and end-all outcome?","volume":"72","author":"Zacharioudakis","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B40","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.cmi.2020.01.023","article-title":"Follow-up blood cultures are associated with improved outcome of patients with gram-negative bloodstream infections: retrospective observational cohort study","volume":"26","author":"Giannella","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026020904073094800_ciaf472-B41","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1093\/cid\/ciz257","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2026020904073094800_ciaf472-B42","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cmi.2020.01.025","article-title":"Positive follow-up blood cultures identify high mortality risk among patients with Gram-negative bacteraemia","volume":"26","author":"Maskarinec","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2026020904073094800_ciaf472-B43","author":"PINC AI\u2122 Applied Sciences, Premier Inc"},{"key":"2026020904073094800_ciaf472-B44"},{"key":"2026020904073094800_ciaf472-B45","doi-asserted-by":"crossref","first-page":"ofad703","DOI":"10.1093\/ofid\/ofad703","article-title":"Healthcare resource utilization and discharge readiness in adult hospitalized patients with candidemia or invasive candidiasis who received an echinocandin: an analysis of United States hospitals","volume":"11","author":"Lodise","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026020904073094800_ciaf472-B46","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"2026020904073094800_ciaf472-B47","first-page":"319","article-title":"Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials","volume":"24","author":"George","year":"2023","journal-title":"Lancet"},{"key":"2026020904073094800_ciaf472-B48","author":"Premier Applied Sciences\u00ae, Premier Inc"},{"key":"2026020904073094800_ciaf472-B49","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra1315399","article-title":"Invasive candidiasis","volume":"373","author":"Kullberg","year":"2015","journal-title":"N Engl J Med"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf472\/64177506\/ciaf472.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/75\/64177506\/ciaf472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/82\/1\/75\/64177506\/ciaf472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:07:42Z","timestamp":1770628062000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/82\/1\/75\/8245298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,9,1]]},"published-print":{"date-parts":[[2026,2,9]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf472","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1,15]]},"published":{"date-parts":[[2025,9,1]]}}}